572 related articles for article (PubMed ID: 8824461)
1. Aromatase inhibitors: rationale for use following antiestrogen therapy.
Yue W; Santen RJ
Semin Oncol; 1996 Aug; 23(4 Suppl 9):21-7. PubMed ID: 8824461
[TBL] [Abstract][Full Text] [Related]
2. Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice.
Yao K; Lee ES; Bentrem DJ; England G; Schafer JI; O'Regan RM; Jordan VC
Clin Cancer Res; 2000 May; 6(5):2028-36. PubMed ID: 10815929
[TBL] [Abstract][Full Text] [Related]
3. The effect of second-line antiestrogen therapy on breast tumor growth after first-line treatment with the aromatase inhibitor letrozole: long-term studies using the intratumoral aromatase postmenopausal breast cancer model.
Long BJ; Jelovac D; Thiantanawat A; Brodie AM
Clin Cancer Res; 2002 Jul; 8(7):2378-88. PubMed ID: 12114443
[TBL] [Abstract][Full Text] [Related]
4. Aromatase inhibitors for treatment of breast cancer: current concepts and new perspectives.
Santen RJ
Breast Cancer Res Treat; 1986; 7 Suppl():S23-35. PubMed ID: 3527304
[TBL] [Abstract][Full Text] [Related]
5. Molecular Action and Clinical Relevance of Aromatase Inhibitors.
Murphy MJ
Oncologist; 1998; 3(2):129-130. PubMed ID: 10388095
[TBL] [Abstract][Full Text] [Related]
6. Predictions from a preclinical model: studies of aromatase inhibitors and antiestrogens.
Brodie A; Jelovac D; Long BJ
Clin Cancer Res; 2003 Jan; 9(1 Pt 2):455S-9S. PubMed ID: 12538500
[TBL] [Abstract][Full Text] [Related]
7. Preclinical studies using the intratumoral aromatase model for postmenopausal breast cancer.
Brodie A; Lu Q; Liu Y; Long B; Wang JP; Yue W
Oncology (Williston Park); 1998 Mar; 12(3 Suppl 5):36-40. PubMed ID: 9556790
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of aromatase as treatment of breast carcinoma in postmenopausal women.
Santen RJ; Boucher AE; Santner SJ; Henderson IC; Harvey H; Lipton A
J Lab Clin Med; 1987 Mar; 109(3):278-89. PubMed ID: 3546561
[TBL] [Abstract][Full Text] [Related]
9. [Aromatase inhibitors--new possibilities in treatment of breast carcinoma].
Friedrichs K; Jänicke F
Praxis (Bern 1994); 1998 Apr; 87(17):584-8. PubMed ID: 9623325
[TBL] [Abstract][Full Text] [Related]
10. Endocrine management of breast cancer.
Schneider PG; Jackisch C; Brandt B
Int J Fertil Menopausal Stud; 1994; 39 Suppl 2():115-27. PubMed ID: 7874188
[TBL] [Abstract][Full Text] [Related]
11. Adaptive hypersensitivity to estrogen: mechanisms and clinical relevance to aromatase inhibitor therapy in breast cancer treatment.
Santen RJ; Song RX; Zhang Z; Kumar R; Jeng MH; Masamura S; Lawrence J; MacMahon LP; Yue W; Berstein L
J Steroid Biochem Mol Biol; 2005 May; 95(1-5):155-65. PubMed ID: 16024245
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of the phosphatidylinositol 3-kinase/Akt pathway improves response of long-term estrogen-deprived breast cancer xenografts to antiestrogens.
Sabnis G; Goloubeva O; Jelovac D; Schayowitz A; Brodie A
Clin Cancer Res; 2007 May; 13(9):2751-7. PubMed ID: 17473209
[TBL] [Abstract][Full Text] [Related]
13. A new nude mouse model for postmenopausal breast cancer using MCF-7 cells transfected with the human aromatase gene.
Yue W; Zhou D; Chen S; Brodie A
Cancer Res; 1994 Oct; 54(19):5092-5. PubMed ID: 7923123
[TBL] [Abstract][Full Text] [Related]
14. Optimizing adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer: a decision analysis.
Punglia RS; Kuntz KM; Winer EP; Weeks JC; Burstein HJ
J Clin Oncol; 2005 Aug; 23(22):5178-87. PubMed ID: 15998905
[TBL] [Abstract][Full Text] [Related]
15. Aromatase inhibitors and breast cancer.
Brodie AM; Njar VC
Semin Oncol; 1996 Aug; 23(4 Suppl 9):10-20. PubMed ID: 8824460
[TBL] [Abstract][Full Text] [Related]
16. Benefits of complete polyamine deprivation in hormone responsive and hormone resistant MCF-7 human breast adenocarcinoma in vivo.
Leveque J; Foucher F; Havouis R; Desury D; Grall JY; Moulinoux JP
Anticancer Res; 2000; 20(1A):97-101. PubMed ID: 10769640
[TBL] [Abstract][Full Text] [Related]
17. Adaptation of estrogen-regulated genes in long-term estradiol deprived MCF-7 breast cancer cells.
Santen RJ; Lobenhofer EK; Afshari CA; Bao Y; Song RX
Breast Cancer Res Treat; 2005 Dec; 94(3):213-23. PubMed ID: 16258703
[TBL] [Abstract][Full Text] [Related]
18. Tamoxifen-resistant fibroblast growth factor-transfected MCF-7 cells are cross-resistant in vivo to the antiestrogen ICI 182,780 and two aromatase inhibitors.
McLeskey SW; Zhang L; El-Ashry D; Trock BJ; Lopez CA; Kharbanda S; Tobias CA; Lorant LA; Hannum RS; Dickson RB; Kern FG
Clin Cancer Res; 1998 Mar; 4(3):697-711. PubMed ID: 9533540
[TBL] [Abstract][Full Text] [Related]
19. Effects of a new clinically relevant antiestrogen (GW5638) related to tamoxifen on breast and endometrial cancer growth in vivo.
Dardes RC; O'Regan RM; Gajdos C; Robinson SP; Bentrem D; De Los Reyes A; Jordan VC
Clin Cancer Res; 2002 Jun; 8(6):1995-2001. PubMed ID: 12060645
[TBL] [Abstract][Full Text] [Related]
20. Approval summary: letrozole in the treatment of postmenopausal women with advanced breast cancer.
Cohen MH; Johnson JR; Li N; Chen G; Pazdur R
Clin Cancer Res; 2002 Mar; 8(3):665-9. PubMed ID: 11895893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
